Rock Springs Capital Management LP Nurix Therapeutics, Inc. Transaction History

Rock Springs Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$12.94 - $29.65 $4.15 Million - $9.52 Million	-321,050 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $68,718 - $89,700	2,600 Added 0.82%	321,050 $9.29 Million
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $70,401 - $113,739	3,100 Added 0.98%	318,450 $9.54 Million
Q2 2021 Aug 16, 2021	BUY	$24.21 - $35.89 $106,524 - $157,916	4,400 Added 1.42%	315,350 $8.37 Million
Q1 2021 May 17, 2021	BUY	$26.98 - $50.17 $1.45 Million - $2.69 Million	53,700 Added 20.87%	310,950 $9.67 Million
Q4 2020 Feb 16, 2021	SELL	$22.85 - $48.44 $6,032 - $12,788	-264 Reduced 0.1%	257,250 $8.46 Million
Q3 2020 Nov 16, 2020	BUY	$16.05 - $34.91 $4.13 Million - $8.99 Million	257,514 New	257,514 $8.99 Million

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $935M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.